Drugs for Covid-19
The Medical Letter on Drugs and Therapeutics
- Table: Treatments Considered for COVID-19
- COVID-19 Vaccine Comparison Chart
- In Brief: Guillain-Barré Syndrome with the Johnson & Johnson COVID-19 Vaccine
- In Brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 Vaccines (online only)
- An EUA for Tocilizumab (Actemra) for COVID-19
- An EUA for Sotrovimab for Treatment of COVID-19
- In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Adolescents 12-15 Years Old
- Fluvoxamine for COVID-19?
- In Brief: Suspension of Johnson & Johnson COVID-19 Vaccine Lifted (online only)
- In Brief: Johnson & Johnson COVID-19 Vaccine Suspended (online only)
- FDA Authorizes Johnson & Johnson COVID-19 Vaccine
- An EUA for Bamlanivimab and Etesevimab for COVID-19
- FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine
- FDA Authorizes Moderna COVID-19 Vaccine
- Remdesivir (Veklury) for COVID-19
- An EUA for Bamlanivimab - A Monoclonal Antibody for COVID-19
- An EUA for Casirivimab and Imdevimab for COVID-19
- An EUA for Baricitinib (Olumiant) for COVID-19
- Timing of Remdesivir for COVID-19
Some helpful resources:
- National Institutes of Health — Coronavirus Disease 2019 (COVID-19) Treatment Guidelines
- US Centers for Disease Control and Prevention — Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19)
- Infectious Diseases Society of America — Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
- World Health Organization — Clinical Management of Severe Acute Respiratory Infection When COVID-19 is Suspected
- Surviving Sepsis Campaign — COVID-19 Guidelines
- JAMA — Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review
- ASHP — Assessment of Evidence for COVID-19-Related Treatments
- BMJ Best Practice — Coronavirus Disease 2019 (COVID-19)
- Annals of Pharmacotherapy — Myth Busters: Dietary Supplements and COVID-19
- Vaccines - COVID-19 vaccines are on the fast-track to approval. How will we know they're safe?
To support more content like this,
please consider making a donation* or becoming a subscriber.
Because the source matters.
The Medical Letter is a nonprofit organization* that relies solely on subscription fees and donations to support our mission of providing objective, practical, and timely information on drugs and therapeutics.
Our work relies on support from people like you who value credible, unbiased drug information that is free of any commercial interest.
Subscribe for less than $3/week.
*The Medical Letter is a nonprofit, tax-exempt organization under Section 501(C)(3) of the Internal Revenue Code. Donations are tax-deductible as allowed by law.
